Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France.
Marcellin P, Zoulim F, Hézode C, Causse X, Roche B, Truchi R, Pauwels A, Ouzan D, Dumortier J, Pageaux GP, Bourlière M, Riachi G, Zarski JP, Cadranel JF, Tilliet V, Stern C, Pétour P, Libert O, Consoli SM, Larrey D. Marcellin P, et al. Among authors: cadranel jf. Dig Dis Sci. 2016 Oct;61(10):3072-3083. doi: 10.1007/s10620-015-4027-8. Epub 2016 Jan 28. Dig Dis Sci. 2016. PMID: 26821154 Free PMC article.
High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.
Marcellin P, Cadranel JF, Fontanges T, Poynard T, Pol S, Trepo C, Blin P, Bregman B, Schmidely N, Roudot-Thoraval F, Zarski JP. Marcellin P, et al. Among authors: cadranel jf. Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1290-6. doi: 10.1097/meg.0b013e32832fba4f. Eur J Gastroenterol Hepatol. 2010. PMID: 20964259
Impact of IL28B on the treatment decision in naïve and experienced patients with genotype 1 and 4 chronic hepatitis C in real-life clinical practice: a prospective multicenter cohort.
Halfon P, Ouzan D, Asselah T, Renou C, Allègre T, Delasalle P, Lafeuillade A, Cadranel JF, Haddad N, Khiri H, Pénaranda G, Bourlière M; Iliade Investigators. Halfon P, et al. Among authors: cadranel jf. Clin Res Hepatol Gastroenterol. 2014 Dec;38(6):720-6. doi: 10.1016/j.clinre.2014.06.004. Epub 2014 Jul 14. Clin Res Hepatol Gastroenterol. 2014. PMID: 25034356
Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH).
Pariente A, Arpurt JP, Rémy AJ, Rosa-Hézode I, Causse X, Heluwaert F, Macaigne G, Henrion J, Renou C, Schnee M, Salloum H, Hommel S, Pilette C, Arotcarena R, Barjonet G, Lison H, Bourhis F, Jouannaud V, Pauwels A, Le eaBricquir Y, Geagea E, Condat B, Ripault MP, Zanditenas D, de Montigny-Lenhardt S, Labadie H, Tissot B, Maringe E, Cadranel JF, Hagège H, Lesgourgues B; Association nationale des gastroentérologues des hôpitaux (ANGH). Pariente A, et al. Among authors: cadranel jf. Presse Med. 2019 Mar;48(3 Pt 1):e101-e110. doi: 10.1016/j.lpm.2018.06.019. Epub 2019 Mar 8. Presse Med. 2019. PMID: 30853287
Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta.
Roulot D, Brichler S, Layese R, BenAbdesselam Z, Zoulim F, Thibault V, Scholtes C, Roche B, Castelnau C, Poynard T, Chazouillères O, Ganne N, Fontaine H, Gournay J, Guyader D, Le Gal F, Nahon P, Roudot-Thoraval F, Gordien E; Deltavir study group. Roulot D, et al. J Hepatol. 2020 Nov;73(5):1046-1062. doi: 10.1016/j.jhep.2020.06.038. Epub 2020 Jul 4. J Hepatol. 2020. PMID: 32634548 Free article.
Efficacy and safety of treatment of chronic hepatitis C with sofosbuvir and ribavirin with or without peginterferon: a French prospective real-life cohort study of unselected 211 patients.
Garioud A, Heng R, Amiot X, Rémy AJ, Ollivier-Hourmand I, Mokhtari C, Medmoun M, Renou C, Zougmoré H, Pulwermacher P, Lucidarme D, Rosa-Hézode I, Causse X, Arotcarena R, Zanditenas D, Halfon P, Pariente A, Cadranel JF; Association Nationale des Hépato-gastroentérologues des Hôpitaux Généraux (ANGH), France. Garioud A, et al. Among authors: cadranel jf. Eur J Gastroenterol Hepatol. 2019 Oct;31(10):1270-1274. doi: 10.1097/MEG.0000000000001450. Eur J Gastroenterol Hepatol. 2019. PMID: 31219848 Clinical Trial.
Diabetes mellitus during interferon therapy for chronic viral hepatitis.
Mofredj A, Howaizi M, Grasset D, Licht H, Loison S, Devergie B, Demontis R, Cadranel JF. Mofredj A, et al. Among authors: cadranel jf. Dig Dis Sci. 2002 Jul;47(7):1649-54. doi: 10.1023/a:1015852110353. Dig Dis Sci. 2002. PMID: 12141831 Review. No abstract available.
Hepatogastroenterologists' knowledge of inactive carriers and immunotolerant hepatitis B virus patients in France: results of a practice survey.
Causse X, Cadranel JF, Potier P, Hanslik B, Denis J, Renou C, Delasalle P; Club de Réflexion des Cabinets et Groupes d’Hépato-Gastroentérologie (CREGG); Association Nationale des hépato-Gastroentérologues des Hôpitaux généraux de France (ANGH). Causse X, et al. Among authors: cadranel jf. Eur J Gastroenterol Hepatol. 2015 May;27(5):544-9. doi: 10.1097/MEG.0000000000000306. Eur J Gastroenterol Hepatol. 2015. PMID: 25822863
Effects of ursodeoxycholic acid (ursodiol) treatment on chronic viral hepatitis in heart transplant patients: results of a prospective, double-blind, placebo-randomized study.
Cadranel JF, Di Martino V, Dorent R, Bernard B, Hoang C, Myara A, Pauwels A, Ghoussoub JJ, Perrin M, Grippon P, Thabut D, Trivin F, Huraux JM, Gandjbakhch I, Opolon P, Lunel F. Cadranel JF, et al. Transplantation. 2003 Apr 15;75(7):977-82. doi: 10.1097/01.TP.0000055831.63841.B6. Transplantation. 2003. PMID: 12698083 Clinical Trial.
236 results